Australia markets closed

Veradigm Inc. (MDRX)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
7.55-0.30 (-3.82%)
At close: 03:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.85
Open7.65
Bid0.00 x 0
Ask0.00 x 0
Day's range7.55 - 7.95
52-week range5.01 - 14.09
Volume114,135
Avg. volume3,895,641
Market cap812.682M
Beta (5Y monthly)0.63
PE ratio (TTM)8.78
EPS (TTM)0.86
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date07 Oct 2008
1y target est13.60
  • Business Wire

    Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings

    CHICAGO, April 09, 2024--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Ambulatory EHR PM Family Practice and Ambulatory EHR PM Primary Care General Practice within its 2024 Top Client/User-Rated Electronic Health Records & Practice Management Solutions report.

  • Business Wire

    Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

    CHICAGO, March 14, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm Interim Chief Executive Officer and board member, Lee Westerfield, Interim Chief Financial Officer, and Will Manidis Co-Founder of ScienceIO will participate in a fireside chat at the KeyBanc Capital Markets Life Science & MedTech Investor Forum on Tuesday, March 19th, 2024 at 12:00 PM EDT.

  • Business Wire

    Veradigm Announces Initial Financial Guidance for Fiscal 2024

    CHICAGO, March 13, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Company’s Form 8-K filed on January 10, 2024, and initially reaffirmed on February 27, 2024.